Our program meets the highest standards set by the National Hemophilia Foundation for a Comprehensive Hemophilia Center including an experienced team of adult and pediatric hematologists, clinical nurse specialists, adult and pediatric orthopedists, physical therapist, on-site coagulation laboratory, infectious disease specialists, hepatologists, and a full range of anti-hemophilic factor products. Hemophilia centers throughout New England refer patients to Dartmouth Hitchcock Medical Center (DHMC) for orthopedic surgery, radionuclide synovectomy, and diagnostic coagulation evaluation services.
The Public Health Service 340B Drug Pricing Program Program is a federal discount program available to HTCs and other covered entities. Our Hemophilia Program was the second hemophilia center in the nation to be an "approved covered entity" which enables patients to receive a significant cost reduction (estimated to be 15 to 20 percent) for certain product purchase from the Public Health Service (called "340B pricing"). For more information, see our brochure (PDF) describing the discount program.
We have the only onsite diagnostic coagulation lab within a 100-mile radius of Lebanon, NH, and the only diagnostic coagulation clinic in New Hampshire. In 2007 we conducted 298 pediatric and adult new patient workups for congenital thrombosis and bleeding disorders. Clinic evaluations are held twice weekly.
Our program currently follows over 300 patients with inherited bleeding disorders. Patients live an average of 100 miles round trip from DHMC. Our Blood Bank is the only facility within a 100 mile radius to maintain a full complement of hemophilia products to manage any hemophilia problem or emergency.
Research interests of physicians and scientists at Dartmouth Cancer Center include:
- Innovative treatment approaches for bleeding and thrombosing disorders, and mechanisms and management of blood coagulation activation in malignancy
- Control of cancer growth by the blood coagulation mechanism
- Role of iron accumulation and age-related disease risk
- Development of novel treatment protocols for rare bleeding disorders